Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926741 · ClinicalTrials.gov registry record · Early Phase 1
GSNOR Phenotyping/GSNO Challenge in Severe Asthma
A Early Phase 1 study, sponsored by James Reynolds.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 48
- Enrollment target
NCT03926741: Completed Early Phase 1 study, sponsored by James Reynolds.
NCT03926741 is a Early Phase 1 study that has completed, run by James Reynolds. The registered enrollment target is 48 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03926741, a Early Phase 1 study, has completed, sponsored by James Reynolds.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
Asthma is caused by or worsened by different things in different people. It is because of these differences that not all people with asthma respond the same to all treatments and medicines. If the investigators can better identify the changes in the airways or breathing pipes in patients with asthma, the investigators may be able to help patients make better choices about the medicines or treatments that are most likely to work best for each patient. This research study is about one specific factor that is known to affect asthma in some patients. It involves an increase in the activity of an enzyme that is in people's airways. An enzyme is something that helps a chemical reaction to occur. The enzyme the investigators are studying in this research study is called GSNOR (S-nitrosoglutathione reductase) , and when the activity of this enzyme is increased, the result is that there is less GSNO (S-nitrosoglutathione) . GSNO is a chemical that protects people's airways. The initials stand for S-nitrosoglutathione, (pronounced s-nahy-troh-soh-gloo-tuh-thahy-ohn), and it is naturally produced by the body. It has an important role in regulating respiratory function (breathing) and preventing inflammation (swelling) in the respiratory tract (throat, airways, and lungs). The amount of GSNO found in the body is controlled by the enzyme GSNOR (S-nitrosoglutathione reductase). GSNOR breaks down GSNO. Too much GSNOR leads to low levels of GSNO, and that can cause inflammation (swelling) and loss of airway function in some asthma patients. The only way to measure GSNOR levels currently is with a bronchoscopy procedure where a scope is inserted into the patient's airways, often under sedation. This research study is being done to test the accuracy of another type of test that can be done in the doctor's office, rather than in a procedure area. This non-invasive diagnostic test, called a GSNO Challenge test, may be able to identify which asthma patients have increased activity of
Primary Outcome
The Fractional expired Nitric Oxide, FeNO, is measured by exhaling into a tube connected to the monitoring device. Nitric oxide is one of the breakdown products of GSNO so measuring it in the breath indicates how fast GSNO is metabolized by the lung
Interventions
- DRUG GSNO Challenge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2024-02-29 |
| Phase | Early Phase 1 |
What the finished NCT03926741 record still lists
NCT03926741 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which GSNO Challenge is the first listed.
NCT03926741 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03926741 about?
NCT03926741 is a clinical study titled "GSNOR Phenotyping/GSNO Challenge in Severe Asthma". Asthma is caused by or worsened by different things in different people. It is because of these differences that not all people with asthma respond the same to all treatments and medicines. If the investigators can better identify the changes in the airways or breathing pipes in patients with asthma...
What is the current status of trial NCT03926741?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2019-04-30. Estimated completion is 2024-02-29.
What interventions are being tested in trial NCT03926741?
The interventions under investigation include: GSNO Challenge (DRUG).
Who is sponsoring clinical trial NCT03926741?
This trial is sponsored by James Reynolds, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03926741's enrollment target sits among peer trials
48 541st of 2000 higher than 1,439 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI